Actively Recruiting
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
Led by Okuvision GmbH · Updated on 2026-05-07
70
Participants Needed
5
Research Sites
108 weeks
Total Duration
On this page
Sponsors
O
Okuvision GmbH
Lead Sponsor
C
CONVIDIA clinical research GmbH
Collaborating Sponsor
AI-Summary
What this Trial Is About
Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss. The goal of this pilot study is to evaluate the safety and the effectiveness of transcorneal electrical stimulation (TES) therapy with the OkuStim 2 System in patients with geographic atrophy (GA). Researchers will compare the effects of two different electrical stimuli with a placebo to see if the stimuli are safe and can slow down the progression of the disease. Participants will be randomly assigned to one of these three groups: * TES-treatment with a rectangular stimulus * TES-treatment with a repetitive ramp stimulus * Placebo (sham) treatment Participants will apply the therapy at home, once a week for 30 minutes each over a duration of 1 year.
CONDITIONS
Official Title
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to understand the study and provide informed consent
- 60 years of age or older
- Diagnosis of geographic atrophy due to age-related macular degeneration confirmed by imaging
- The affected area in the eye must be within a defined size range and clearly visible on imaging
- Eye conditions must allow for good-quality images and reliable measurements
- Must have a minimum level of visual acuity
- Women of childbearing potential must have a negative pregnancy test, and must agree to use effective contraception during the study (women who are postmenopausal or surgically sterile are not subject to pregnancy-related requirements)
You will not qualify if you...
- History or presence of certain eye conditions (e.g. macular edema, abnormal blood vessel growth or related conditions, retinal detachment, blood vessel blockage) in the study eye
- Previous major eye surgeries (including retinal surgery or vitrectomy)
- Previous laser treatment or injections in the study eye
- Any other eye condition that could interfere with vision tests, imaging or study results
- Planned eye surgery during the study period
- Recent treatment with investigational drugs for geographic atrophy
- Presence of active medical implants
- Serious or uncontrolled systemic diseases, history of epilepsy or poor general health or conditions affecting the ability to follow study procedures
- Participation in another clinical study recently or at the same time
- Breastfeeding, relevant allergies (e.g. to silver), or heavy smoking
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf
Hamburg, Germany, 20246
Not Yet Recruiting
2
Department of Ophthalmology, Ludwig-Maximilians-University Munich
München, Germany, 80336
Actively Recruiting
3
Department of Ophthalmology, Klinikum Stuttgart
Stuttgart, Germany, 70174
Actively Recruiting
4
Centre for Ophthalmology, University Hospital Tuebingen
Tübingen, Germany, 72076
Actively Recruiting
5
Department of Ophthalmology, University Hospital Ulm
Ulm, Germany, 89075
Not Yet Recruiting
Research Team
R
Ruth Schippert, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here